Psychedelics Didn’t Beat Antidepressants—Here’s Why That Matters

Want the latest research insights delivered straight to your inbox?

mailing list

Psychedelic-assisted therapy (PAT) has been widely promoted as a breakthrough treatment for depression, often showing large effect sizes in early trials. However, a key methodological concern has persisted:

👉 Functional unblinding — patients can almost always tell they received a psychedelic.

This new systematic review and meta-analysis published in JAMA Psychiatry directly addresses this issue by comparing PAT with open-label traditional antidepressants (TADs), creating a more clinically meaningful “real-world” comparison.

Why This Comparison Matters?

Study Design

Design: Systematic review and meta-analysis (PRISMA-compliant)
Data source: PubMed search (March 2024)
Included trials: 24 total
- 8 psychedelic trials (n = 249)
- 16 open-label antidepressant trials (n = 7,921)
Additional dataset: 144 blinded antidepressant trials (n = 31,792) for comparison of blinding effects

Population

Adults with major depressive disorder
Excluded:
- Psychotic depression
- Significant comorbidity (except anxiety)
- Inpatient populations

Key Methodological Approach

Outcomes converted to HAM-D (17-item) equivalents
Primary endpoint:
👉 Within-arm change from baseline to endpoint

Predefined hypotheses:

1. PAT superior to antidepressants
2. Open-label antidepressants superior to blinded
3. Blinding does not affect PAT outcomes

Results:

1. Primary Outcome: PAT vs Antidepressants

No significant difference in efficacy
Mean difference:
- 0.3 HAM-D points (95% CI −1.39 to 1.98; P = .73)
Bayesian estimate similarly negligible (~0.25 HAM-D units)

👉 Importantly:

Difference far below minimum clinically important difference (MCID = 3 points)

2. Absolute Symptom Improvement

Open-label antidepressants:
- ~−12.5 HAM-D points
Psychedelic therapy:
- ~−11.8 HAM-D points

👉 Nearly identical magnitude of improvement

3. Effect of Blinding

Antidepressants:

Open-label > blinded
Difference:
- ~1.29 HAM-D points (statistically significant)
BUT:
- Clinically small (≈ half MCID)

Psychedelics:

No difference between blinded vs open-label trials
Confirms:
👉 Psychedelic trials are effectively always unblinded

4. Why Do Psychedelics Look Better vs Placebo in Prior Studies?

The authors provide a critical explanation:

A. Reduced Placebo Response in Psychedelic Trials

Placebo groups improve ~4 HAM-D points less than in antidepressant trials

B. Expectancy Effects

Open-label antidepressants gain ~1.3 HAM-D points advantage

👉 Combined inflation:

~5 HAM-D points, which explains prior superiority claims

5. Treatment Duration Differences

Antidepressant trials:
- ~8.1 weeks
Psychedelic trials:
- ~3.4 weeks

👉 Despite shorter duration, outcomes were similar

Key Facts from Study:

1. The “Knowcebo” Effect

A key insight from the paper:

Patients in psychedelic trials may feel disappointment when they realize they are in the placebo group, leading to worse outcomes.

Called the “knowcebo” effect
Particularly amplified in psychedelic settings where:
- Patients expect transformative experiences
- Control groups receive minimal subjective effects

👉 This suppresses placebo response and inflates apparent treatment effect

2. Rethinking Psychedelic Superiority

Earlier data:

Psychedelics vs placebo: ~7.3 HAM-D improvement
Antidepressants vs placebo: ~2.4 HAM-D improvement

This paper shows:
👉 Much of this difference is methodological, not pharmacological

3. Within-Arm vs Between-Arm Effects

Important nuance:

This study focuses on within-arm improvement
Includes:
- Drug effects
- Placebo
- Natural recovery
- Therapeutic setting

👉 Reflects real-world clinical benefit, not just drug-specific effects

4. Functional Unblinding Is Central

Psychedelic trials:
- 90–95% correct guess rate
Antidepressant trials:
- ~63% correct guess rate

👉 This fundamentally alters trial validity

5. Other Key Observations

Psychedelic trials:
- More educated participants
- Underrepresentation of minorities
Endpoint timing favors psychedelics
Functional outcomes may still differ:
- Some evidence suggests better functional improvement with psychedelics at follow-up

Limitations:

Key Clinical Takeaways

Psychedelic therapy:
- Effective, but not superior to antidepressants

Expectancy and trial design:
- Play a major role in outcomes

Blinding matters:
- Especially for antidepressant trials

Large psychedelic effect sizes:
- Likely inflated by methodological bias

Expert Commentary (Clinical Perspective)

1. This Is a Pivotal Correction in the Field

This study shifts the narrative from:

👉 “Psychedelics are dramatically superior”

To:

👉 “Psychedelics are comparable under fair conditions”

2. The Real Story: Context Matters

This paper reinforces a core psychiatric principle:

Treatment outcomes are heavily influenced by expectation, setting, and therapeutic engagement

In fact:

These may explain a substantial portion of antidepressant response

3. Where Psychedelics Still Fit

Despite lack of superiority, psychedelics may offer:

Rapid onset
Strong patient engagement
Potential benefits in:
- Treatment-resistant depression
- Existential distress
- Psychotherapy integration

👉 But they should not yet replace standard care

4. Clinical Practice Implications

For now:

Antidepressants remain first-line
Psychedelic therapy:
- Should be used in specialized settings
- Requires structured psychological support
Be cautious about:
- Overinterpreting early trial data
- Patient expectations driven by media

5. Future Direction

The most important question moving forward is:

👉 Not “Which is better?”
👉 But “How do we optimize both?”

Potential model:

Rapid-acting intervention (psychedelic/ketamine)
Combined with:
- Structured psychotherapy
- Long-term pharmacologic support

Bottom Line

This landmark meta-analysis provides a critical recalibration:

👉 Psychedelic therapy is not superior to antidepressants when expectancy bias is controlled

But it remains:

A promising tool
With unique experiential and therapeutic value

The next phase of research must focus on:

Patient selection
Long-term outcomes
Integration into standard psychiatric care

DEEP DIVE FOR ACADEMY MEMBERS:

(1) Psilocybin for Treatment-Resistant Depression

This discussion will focus on following clinically relevant topics:

Psilocybin sessions: Administrative and Integration sessions.
Results: (a) Response; (b) Remissions; (3) Sustained Response
Comparing Psilocybin Response to: (q) Antidepressants; (b) STAR*D
Common and Serious Adverse Events with Psilocybin.

Psilocybin for Treatment-Resistant Depression

[Journal Club]

LEARN MORE

ACADEMY

(2) Psilocybin for Treatment-Resistant Bipolar 2 Depression

This discussion will be summarized in the following sections:

Study Discussion: Design, Results and Conclusions.
How Early was the Response seen with psilocybin?
Did Response and Remission persisted till week 12?
Risk of manic switches with psilocybin trial?
Risk of worsening suicidality with psilocybin trial?
What is the predictor of long-term antidepressant response with psilocybin?
Common adverse events with psilocybin.

Psilocybin for Treatment-Resistant Bipolar 2 Depression